Cystnil150 mg+550 mg

Established / Guideline-Supported Use

• Polycystic Ovary Syndrome (PCOS): Cystnil is commonly used, and supported by several clinical studies and referenced in some international PCOS management guidelines as a second-line/adjunctive option, to help improve insulin sensitivity, restore regular ovulation, and improve metabolic parameters (e.g. lipid profile, androgen levels) in women with PCOS.

Adjunct / Combination-Therapy Use

• Adjunct to lifestyle modification and fertility treatment: Cystnil is sometimes used alongside diet, exercise, or assisted reproduction protocols (e.g. ovulation induction, IVF) to potentially improve oocyte quality and metabolic status, generally as an adjunct rather than a stand-alone fertility treatment.

Off-Label / Investigational Use

• Some studies have explored Cystnil for reducing the risk of gestational diabetes in pregnant women with risk factors; this use is investigational and not an established indication.

Important: This is not an FDA-approved prescription medicine; evidence supporting its use is more limited than for conventional pharmacotherapy. Cystnil should be used as directed by a physician and is not a substitute for prescribed treatment where one is indicated.

D-chiro-inositol + Myo-inositol is a combination nutraceutical/dietary supplement containing two naturally occurring stereoisomers of inositol: myo-inositol and D-chiro-inositol. It is most commonly formulated in a physiological plasma ratio of approximately 40:1 (myo-inositol:D-chiro-inositol), for example 2000 mg myo-inositol combined with 50 mg D-chiro-inositol per sachet/capsule, though exact strengths vary by manufacturer and product presentation (powder sachet, capsule, or tablet).

Cystnil is a combined insulin-sensitizing inositol stereoisomer supplement, not a conventional single-molecule pharmaceutical drug and not FDA-approved as a prescription medicine. It is marketed as a dietary supplement/nutraceutical, most often used as adjunctive support in women with polycystic ovary syndrome (PCOS) to help improve insulin sensitivity and support ovulatory and metabolic function.

Myo-inositol and D-chiro-inositol are both naturally occurring in the body and in the diet (found in fruits, beans, grains, and nuts) and act as precursors of insulin second-messenger molecules. In women with PCOS, an imbalance in the conversion of myo-inositol to D-chiro-inositol in ovarian tissue has been proposed as a contributing mechanism to insulin resistance and abnormal ovarian steroidogenesis; combined supplementation with Cystnil in a physiological ratio is intended to help restore this balance.

Cystnil belongs to the class of insulin-sensitizing nutraceuticals/dietary supplements (inositol stereoisomer combination). It is not classified as a prescription drug under conventional pharmacologic drug classes such as biguanides or thiazolidinediones, although it is used for a related purpose (improving insulin sensitivity).

Mechanism of action: Myo-inositol and D-chiro-inositol are both inositol stereoisomers that act as precursors of inositolphosphoglycan (IPG) second-messenger molecules involved in intracellular insulin signal transduction. Myo-inositol also serves as a precursor for the phosphatidylinositol pathway involved in follicle-stimulating hormone (FSH) signaling within the ovary, supporting normal follicular development. D-chiro-inositol is involved in insulin-stimulated glycogen synthesis and has been shown to modulate ovarian androgen (testosterone) production.

In women with PCOS, tissue-specific conversion of myo-inositol to D-chiro-inositol in the ovary may be abnormal, contributing to reduced insulin sensitivity and disrupted ovarian function. D-chiro-inositol + Myo-inositol, given in a combined formulation approximating the physiological plasma ratio (commonly 40:1 myo-inositol to D-chiro-inositol), is intended to help correct this imbalance, thereby supporting improved insulin sensitivity, more regular ovulatory cycles, and modest improvements in circulating androgen and lipid levels in some studies.

Cystnil is typically supplied as an oral powder sachet (dissolved in a glass of water), capsule, or tablet. It may be taken with or without food, though taking it with meals may reduce the chance of mild gastrointestinal upset. Doses are usually spaced approximately 12 hours apart (e.g. once in the morning and once in the evening). It should be taken consistently as directed by a physician for the recommended duration to assess benefit.

Well-documented, clinically significant drug interactions are limited, reflecting its status as a nutraceutical rather than a conventional pharmaceutical. Notable points include:

• Anti-diabetic medications (e.g. metformin, sulfonylureas, insulin): Because Cystnil has an insulin-sensitizing effect, concurrent use with anti-diabetic drugs may have an additive effect on blood glucose lowering; blood glucose should be monitored and dose adjustment of anti-diabetic medication considered by the treating physician.
• Other supplements/herbal products with glucose-lowering effects: Combining Cystnil with other glucose-lowering supplements may theoretically increase the risk of hypoglycemia-like symptoms; caution and medical supervision are advised.

Patients should inform their physician of all medications and supplements they are taking before starting Cystnil.

Cystnil is generally well tolerated. When side effects occur, they are usually mild and dose-related, most commonly involving the gastrointestinal tract:

• Nausea
• Abdominal bloating or discomfort
• Flatulence
• Mild diarrhea or loose stools, particularly at higher doses
• Headache (uncommon)

Serious adverse effects are rare. Patients who experience severe or persistent symptoms should stop use of Cystnil and consult a physician.

Data on the use of Cystnil during pregnancy and lactation are limited. Although myo-inositol has been studied in some trials for reducing gestational diabetes risk in at-risk pregnant women, robust safety data for the combined Cystnil formulation in pregnancy and breastfeeding are not well established. Cystnil should be used during pregnancy or while breastfeeding only if clearly needed and under the guidance of a physician, who can weigh the potential benefit against any potential risk. It should not be self-initiated during pregnancy without medical advice.

Cystnil is a dietary supplement/nutraceutical and is not a substitute for prescribed medical therapy for PCOS, diabetes, or infertility. Patients should continue any physician-prescribed treatment unless advised otherwise.

• Use with caution in patients with diabetes or those on anti-diabetic medication, due to a potential additive glucose-lowering effect (see Interactions).
• Hypersensitivity: discontinue Cystnil if signs of an allergic reaction occur (see Contraindications).
• Product quality, exact ratio, and strength can vary between manufacturers since this is regulated as a supplement in many markets rather than as a prescription drug; patients should use products from reputable sources.
• Cystnil should be used under medical supervision, particularly in women with PCOS who are also trying to conceive or undergoing fertility treatment.

There is limited formal data on overdose with Cystnil. Taking substantially more than the recommended dose is likely to increase the chance and severity of gastrointestinal side effects such as nausea, vomiting, abdominal cramping, and diarrhea. There is no specific antidote. If a large overdose is suspected or if severe or persistent symptoms occur, seek immediate medical attention or contact a poison control center/emergency services; do not attempt specific home treatment beyond general supportive measures advised by a healthcare professional.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Renal impairment: No well-established dose adjustment for Cystnil in renal impairment; use with caution and physician guidance, as inositol is renally cleared.
• Hepatic impairment: No well-established dose adjustment; limited data available for Cystnil in hepatic impairment.
• Elderly: Cystnil is not typically indicated in elderly populations, as its primary use (PCOS) applies to women of reproductive age; limited safety data exist in older adults.
• Diabetic patients: May be used under medical supervision with monitoring of blood glucose given the insulin-sensitizing effect (see Interactions).

Cystnil is typically used for a trial period of at least 3 to 6 months, as improvements in ovulatory cycles and metabolic parameters in PCOS are usually assessed over this timeframe. The treating physician should periodically reassess response and determine whether continued use of Cystnil is appropriate.

Nutraceutical / dietary supplement; insulin-sensitizing agent; inositol stereoisomer combination

Mechanism of action: Myo-inositol and D-chiro-inositol are both inositol stereoisomers that act as precursors of inositolphosphoglycan (IPG) second-messenger molecules involved in intracellular insulin signal transduction. Myo-inositol also serves as a precursor for the phosphatidylinositol pathway involved in follicle-stimulating hormone (FSH) signaling within the ovary, supporting normal follicular development. D-chiro-inositol is involved in insulin-stimulated glycogen synthesis and has been shown to modulate ovarian androgen (testosterone) production.

In women with PCOS, tissue-specific conversion of myo-inositol to D-chiro-inositol in the ovary may be abnormal, contributing to reduced insulin sensitivity and disrupted ovarian function. D-chiro-inositol + Myo-inositol, given in a combined formulation approximating the physiological plasma ratio (commonly 40:1 myo-inositol to D-chiro-inositol), is intended to help correct this imbalance, thereby supporting improved insulin sensitivity, more regular ovulatory cycles, and modest improvements in circulating androgen and lipid levels in some studies.

Safety and efficacy of Cystnil in children and pre-menarchal adolescents have not been established, and Cystnil is not indicated in this population. In adolescent girls with a confirmed diagnosis of PCOS after menarche, Cystnil has been used in some limited studies under specialist (pediatric endocrinology or gynecology) supervision, but it should not be used in adolescents without medical guidance and a confirmed diagnosis.